Skip to content

Normotensive and Hypertensive Placental Abruptions

Comparison of Maternal Neonatal Outcomes of Normotensive and Hypertensive Placental Abruptions: A Novel Approach

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04449601
Enrollment
115
Registered
2020-06-29
Start date
2016-01-01
Completion date
2017-11-30
Last updated
2020-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abruptio Placentae; Affecting Fetus or Newborn

Keywords

Abruptio placenta, complete blood count, hypertension, perinatal outcome., mean platelet volume

Brief summary

Placental abruption is a significant cause of both maternal morbidity and neonatal morbidity and mortality. Most abruptions accept to be related to a chronic placental disease process. Therefore, it is very important to understand these processes. To analyze maternal and neonatal effects of placental abruption(PA) through a novel classification in the presence of hypertension. Initial hemoglobin parameters were also compared to predict pregnancy outcomes in addition to hypertension.

Detailed description

Objective: We aimed to classify placental abruption according to hypertension status. Methods: This retrospective cohort designed study was conducted on 115 pregnant women with placental abruption. The main parameters scanned and recorded from the hospital database and patient medical files. Two groups were classified regarding of presence or absence of hypertension (53 hypertensive, 62 normotensive). Maternal demographical and clinical characteristics (abdominal pain, vaginal bleeding) were recorded. APGAR scores below 5 at 1 and 5 min., fetal or neonatal death, admission and length of stay in Neonatal Intensive Care Unit(NICU) were also investigated and compared between the groups.

Interventions

Comparison of Hypertensive group and normotensive group

Sponsors

Hatice Akkaya
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* spontaneous, * singleton pregnancies * above 25 weeks of gestations with positive fetal cardiac activity

Exclusion criteria

* multiple gestations, * presence of fetal or maternal infection, * chronic inflammatory diseases or connective tissue disorders * history of myocardial infarction, * thrombosis * history of steroid drug usage.

Design outcomes

Primary

MeasureTime frameDescription
blood pressure measurement2 minutemm Hg

Secondary

MeasureTime frameDescription
hemogram parameters WBC(white blood cell) ,PLT(Platelet), MPV(mean platelet volume), HGB(hemoglobin), Neutrophil lymphocyte ratio..)first 1 hourcomplete blood test retrospective complete blood count analysis
maternal and newborn length, weight5 minutecentimeters,kilogram
APGAR score5 minute1st and 5th minute newborn assesment

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026